News
FesariusTherapeutics Closes Oversubscribed $20M Series A, Led by Jefferson Life Sciences, and Backed by NY Ventures, and the American Society of Plastic Surgeons
Overview
FesariusTherapeutics, a commercial-stage medical technology company reimagining dermal repair, today announced the close of an oversubscribed $20 million Series A financing round. The round was anchored by Jefferson Life Sciences (JLS) and joined by Johnson & Johnson (through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc.), Empire State Development’s NY Ventures, and the American Society of Plastic Surgeons (ASPS), marking its inaugural institutional investment. The financing marks a significant milestone for Fesarius, validating its technology in the clinic, building commercial momentum across U.S. hospital systems, and positioning the company for its next phase of growth.
The Big Picture
The $1.6 billion U.S. market for dermal regeneration has seen virtually no innovation over the last 30 years. As the first of its kind hDRT, DermiSphere’s™ novel dual-density collagen microarchitecture is designed to drive faster cellular infiltration and vascularization to support the body’s natural wound healing process.
